ALK-fusion-positive secondary ameloblastic carcinoma reached complete response after using alectinib. (September 2022) - Li, Siyi; Li, Rongrong; Xia, Jing; Zhang, Zhen; Hu, Longwei; Zhang, Shijian; Sun, Jingjing; Wang, Liya; Wang, Lei; Huang, Mengli; Hao, Chen; Wang, Beibei; et al.